The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease
- 1 May 2023
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 81 (21), 2103-2111
- https://doi.org/10.1016/j.jacc.2023.03.414
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- Cost-Related Nonadherence and Mortality in Patients With Chronic Disease: A Multiyear Investigation, National Health Interview Survey, 2000–2014Preventing Chronic Disease, 2020
- Out-of-Pocket Costs for Novel Guideline-Directed Diabetes Therapies Under Medicare Part DJAMA Internal Medicine, 2020
- Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid CardiomyopathyCirculation, 2020
- US life expectancy stalls due to cardiovascular disease, not drug deathsProceedings of the National Academy of Sciences of the United States of America, 2020
- Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part DJAMA Cardiology, 2019
- Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor TherapyJAMA Cardiology, 2017
- Nationwide Coverage and Cost-Sharing for PCSK9 Inhibitors Among Medicare Part D PlansJAMA Cardiology, 2017
- Medicare Part D Plans’ Coverage and Cost-Sharing for Acute Rescue and Preventive Inhalers for Chronic Obstructive Pulmonary DiseaseJAMA Internal Medicine, 2017
- Full Coverage for Preventive Medications after Myocardial InfarctionThe New England Journal of Medicine, 2011
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesPLoS Medicine, 2007